Medications with Generic Name Beginning ‘D’

Page 1 of 380 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

PRADAXA (Dabigatran Etexilate Mesylate)

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. PRADAXA is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with…

Rebel Distributors Corp23 November 2010

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

Bryant Ranch Prepack1 October 2019

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

Boehringer Ingelheim Pharmaceuticals Inc.6 July 2020

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

A-S Medication Solutions1 October 2020

Tafinlar (Dabrafenib)

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved…

Novartis Pharmaceuticals Corporation2 July 2020

Page 1 of 380 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Nostrum Laboratories, Inc. Expands Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg, Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit
Sun, 24 Jan 2021. Nostrum Laboratories, Inc. is voluntarily recalling one lot of Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) to the consumer level. The Metformin HCl Extended Release Tablets, USP 750 mg (generic…
Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation
Sun, 10 Jan 2021. Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system. The voluntary…

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.